Sun Pharma launches UNLOXCYT for advanced skin cancer treatment
News by Aliceblue News Desk
16 Jan 2026
Introduction
Leading pharmaceutical company announced US availability of a checkpoint inhibitor for advanced cutaneous squamous cell carcinoma following FDA approval of an updated clinical label.
Also Read: Tata Elxsi Q3 FY26: Stock in focus after profit crashes 45% and marginal revenue growth
Share price movement of Sun Pharma
On January 16, 2026, Sun Pharmaceutical Industries Limited opened at ₹1,709.25, up 0.51% from its previous close of ₹1,700.55. The stock hit a high of ₹1,709.30 and a low of ₹1,670.50. By 10:37 AM, it traded at ₹1,681.50, down 1.12%, with a market capitalisation of ₹4,03,438.67 crore.
Sun Pharma Launches UNLOXCYT in US
Sun Pharmaceutical Industries Limited announced the US availability of UNLOXCYT cosibelimab ipdl for adults with advanced cutaneous squamous cell carcinoma not eligible for curative surgery or radiation in the country.
The FDA approved an updated UNLOXCYT label based on long term data from the CK 301 101 trial showing improved response rates duration of response and unchanged safety profile results.
Trial results showed fifty percent objective response seventy one percent disease control durable responses manageable adverse events and limited distribution availability for UNLOXCYT across specialty channels in the United States.
Stock performance of Sun Pharma for Period of 1 week, 6 months, and 1 year
Sun Pharmaceutical Industries Ltd delivered a -1.69% return over the past week, rose 0.42% in the past 6 months, and fell -3.55% over the past 1 year.
Also Read: Thomas Cook India teams up with Gujarat to drive travel demand, here’s how
Shareholding pattern of Sun Pharma
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 54.50% | 54.50% | 54.50% |
| FII | 16.10% | 16.60% | 17.30% |
| DII | 20.80% | 20.20% | 19.50% |
| Public | 9% | 8.70% | 8.50% |
About Sun Pharma
Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) is India’s largest pharma company, offering generics, innovative medicines, and consumer healthcare, with global operations across 100+ countries.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Sun Pharmaceutical Industries Ltd share price in focus today?
A: Sun Pharma announces US availability of UNLOXCYT for advanced cutaneous squamous cell carcinoma following FDA approval of updated label.
Q: What is Sun Pharmaceutical Industries Ltd’s main business focus?
A: Sun Pharma focuses on generics, innovative medicines in dermatology, ophthalmology, onco-dermatology, and consumer healthcare products globally.
Q: What is the 52-week high and low of Sun Pharmaceutical Industries Ltd stock?
A: Sun Pharma’s 52-week high is ₹1,850.95 and the 52-week low is ₹1,547.25.
News Author
Aliceblue News Desk
